Systemic Chemotherapy Is Modulated by Platelet-Activating Factor-Receptor Agonists

Figure 2

Effect of CPAF on EL4 tumor growth and comparison of basal B16F10 and EL4 tumor growth. (a) Murine syngeneic EL4 lymphoma tumor cells (0.5 × 10⁶) were implanted subcutaneously into the shaved dorsal hind flanks of C57BL/6 WT mice (4-5 mice/group). CPAF treatment (250 ng/mouse) was given intraperitoneally at days 0, 6, and 12. Tumor growth was measured and tumor volumes (major circumference × minor circumference²/2) were compared between the groups. (b) The basal growth rates between B16F10 and EL4 tumors were compared by assessing tumor volumes (major circumference × minor circumference²/2). Statistical differences were noted between EL4 and B16F10 tumors at day 6 (), day 9 (), day 12 (), and day 15 ().

(a)

(b)